Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 23

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
— — — — (4,702,501)(4,702,501)Foreign currency translation adjustments— — — 22,935 — 22,935 Balance at September 30, 20248,546,364 $854 $168,660,520 $(362,625)$(169,783,232)$(1,484,483)

See accompanying notes.

4

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited) 

Nine months ended September 30,20252024Cash flows from operating activitiesNet (loss) income$(11,957,556)$1,452,799 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Depreciation and amortization1,100,091 35,957 Deferred financing cost amortization135,873 21,875 Right-of-use asset - operating lease382,249 350,112 Stock-based compensation expense1,139,402 1,713,996 Loss on disposal of property and equipment — 600,000 Non-cash royalty revenue related to sale of future royalties(4,457)(63,725)Non-cash interest expense187,693 256,295 Changes in operating assets and liabilities:Other receivables(139,175)430,325 Prepaid expenses554,256 2,923,497 Other current assets(53,159)— Other non-current assets(43,652)(48,285)Operating lease liability(405,232)(359,171)Accounts payable366,126 (2,336,871)Accrued expenses(1,006,238)(1,207,805)Interest payable418,007 385,432 Deferred grant funding(2,004,362)(3,986,794)Net cash (used in) provided by operating activities(11,330,134)167,637 Cash flows from investing activitiesPurchases of property and equipment(178,637)(10,197)Net cash used in investing activities(178,637)(10,197)Cash flows from financing activitiesNet proceeds from issuance of common stock19,655,303 398,091 Repayment of liability on sale of future royalties— (1,910)Issuance of note payable486,720 561,663 Payments